Elicit: Real-Time Kidney Damage Markers (public)
What are the most effective real-time markers of kidney cell damage?
Abstract
Real‐time markers for kidney cell damage most consistently report high diagnostic accuracy when measured in the appropriate clinical context and time window. Urinary neutrophil gelatinase‐associated lipocalin (NGAL) rises within 2–6 hours after injury, with studies reporting area under the curve (AUC) values up to 0.91, sensitivities of 84–100%, and specificities as high as 99.5%. Urinary [TIMP‑2]·[IGFBP7] is typically measured at 6–12 hours post‐injury and shows AUC values ranging from 0.70 to 0.94, with reported sensitivities of 42–96% and specificities up to 95%. Urinary kidney injury molecule‑1 (KIM‑1) measured at 12–24 hours post‐insult yields moderate performance (AUC 0.66–0.84) with sensitivities between 75.9% and 91.6% and specificities up to 95.2%.
When combined in multi‐marker panels, these biomarkers often achieve superior performance. For example, panels including NGAL, [TIMP‑2]·[IGFBP7], and cystatin C have produced AUC values as high as 0.98, while combinations with additional markers have reached similar levels of discrimination. These findings, drawn from a diverse set of populations and clinical settings—ranging from cardiac surgery and intensive care to emergency presentations—support the use of NGAL, [TIMP‑2]·[IGFBP7], and KIM‑1 as effective real‐time indicators of kidney cell damage.
Methods
We analyzed 40 sources from an initial pool of 999, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.
Screening
We screened in sources based on their abstracts that met these criteria:
- Real-time Biomarker Detection: Does this study evaluate biomarkers that can detect kidney cell damage in real-time or near real-time (within 24 hours maximum)?
- Human Participants: Does this study involve human participants with actual or potential kidney cell damage?
- Diagnostic Performance Assessment: Does this study assess diagnostic performance metrics (such as sensitivity, specificity, positive/negative predictive values, AUC, or diagnostic accuracy)?
- Appropriate Study Design: Is this study a prospective cohort study, cross-sectional diagnostic accuracy study, randomized controlled trial, systematic review, or meta-analysis?
- Comparative Assessment: Does this study compare novel biomarkers to established reference standards or other biomarkers?
- Clinical Study Setting: Is this study conducted in a clinical setting (not exclusively animal studies, in vitro studies, or cell culture studies)?
- Primary Research Quality: Is this study a primary research study or high-quality secondary research (not a case report, case series, editorial, or opinion piece)?
- Clinical Utility Assessment: Does this study assess the diagnostic performance or clinical utility of biomarkers (not just measure biomarker levels without performance evaluation)?
We considered all screening questions together and made a holistic judgement about whether to screen in each paper.
Data extraction
We asked a large language model to extract each data column below from each paper.
- Study design: Specify the exact type of study design used.
- Participant characteristics: Extract the following details:
- Total number of participants
- Patient population (e.g., critically ill patients, cardiac surgery patients)
- Age range or mean age
- Gender distribution
- Specific inclusion/exclusion criteria
- Biomarkers investigated: List ALL biomarkers examined in the study for detecting kidney cell damage.
- Biomarker performance metrics: Extract quantitative performance data for biomarkers.
- Primary outcome definition: Describe how acute kidney injury (AKI) was defined and diagnosed in the study.
Results
Characteristics of Included Studies
- Most commonly evaluated biomarkers:
- Neutrophil gelatinase-associated lipocalin (NGAL): 29 studies
- Kidney injury molecule-1 (KIM-1): 21 studies
- [TIMP-2]·[IGFBP7]: 12 studies
- Interleukin-18 (IL-18): 11 studies
- Liver-type fatty acid-binding protein (L-FABP): 8 studies
- Cystatin C (CysC): 14 studies
Individual Biomarker Performance
| Biomarker | Area Under the Curve (AUC) Range | Sensitivity Range | Specificity Range |
|---|---|---|---|
| [TIMP-2]·[IGFBP7] | 0.70–0.94 | 42–96% | 50–95% |
| NGAL (urine) | 0.62–0.91 | 55–100% | 64–99.5% |
| KIM-1 (urine) | 0.66–0.84 | 75.9–91.6% | 61.8–95.2% |
| Cystatin C (urine/plasma) | 0.68–0.88 | 71–79.3% | 74.2–92% |
Combined Biomarker Performance
Several studies reported that combinations of biomarkers outperformed individual markers. Key findings from these studies include:
- NGAL, IL-18, and [TIMP-2] yielded an AUC of 0.973.
- Combination of five biomarkers achieved an AUC of 0.98.
- The most effective combinations typically included [TIMP-2]·[IGFBP7] and NGAL.
Timing of Detection and Clinical Context
| Biomarker/Combination | Optimal Detection Window | Clinical Context | Performance Metrics |
|---|---|---|---|
| NGAL (urine) | 2–6 hours post-injury | Pediatric cardiopulmonary bypass, sepsis, ICU | AUC >0.9, Sensitivity 84–100%, Specificity 80–99.5% |
| [TIMP-2]·[IGFBP7] | 6–12 hours post-injury | ICU, cardiac surgery | AUC 0.70–0.94, Sensitivity 89–96% |
| KIM-1 (urine) | 12–24 hours post-injury | Drug-induced, contrast nephropathy | AUC 0.66–0.84, Sensitivity 75.9–91.6% |
Factors Affecting Biomarker Performance
- Performance varied by clinical context, including ICU, surgery, sepsis, drug-induced injury, pediatric, oncology, and neonates.
- Variability in AKI definitions affected comparability across studies.
References
- Ravi J. Desai, C. Kazarov, Adrian Wong, S. Kane‐Gill (2022). Kidney Damage and Stress Biomarkers for Early Identification of Drug-Induced Kidney Injury: A Systematic Review. Drug Safety.
- W. Han, S. Waikar, A. Johnson, R. Betensky, C. Dent, et al. (2008). Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney International.
- J. Koyner, V. Vaidya, M. Bennett, et al. (2010). Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. American Society of Nephrology. Clinical Journal.